-
Expert Opin Pharmacother · Feb 2009
Review Comparative StudyPharmacotherapy of acute coronary syndrome: the ACUITY trial.
- Debabrata Mukherjee and Kim A Eagle.
- Division of Cardiovascular Medicine, Gill Heart Institute, University of Kentucky, 900 S. Limestone Street, 326 Wethington Building, Lexington, KY 40536-0200, USA. Mukherjee@uky.edu
- Expert Opin Pharmacother. 2009 Feb 1; 10 (3): 369-80.
BackgroundBivalirudin, a direct thrombin inhibitor, has unique attributes including predictable pharmacokinetics, a reduction in bleeding complications and avoidance of heparin induced thrombocytopenia.ObjectiveWe critically review the role of bivalirudin in the management of patients with acute coronary syndrome in light of the Acute Catheterization and Urgent Intervention Triage Strategy (ACUITY) trial.MethodsData from the ACUITY trial was critically reviewed along with other contemporary data.Results/ConclusionIn the ACUITY trial, bivalirudin monotherapy was associated with rates of ischemic events that were noninferior to those associated with heparin plus glycoprotein IIb/IIIa inhibition, but was associated with a significantly reduced incidence of major bleeding. Bivalirudin seems to be an attractive antithrombotic agent in patients with acute coronary syndrome undergoing early invasive management.
Notes
Knowledge, pearl, summary or comment to share?You can also include formatting, links, images and footnotes in your notes
- Simple formatting can be added to notes, such as
*italics*
,_underline_
or**bold**
. - Superscript can be denoted by
<sup>text</sup>
and subscript<sub>text</sub>
. - Numbered or bulleted lists can be created using either numbered lines
1. 2. 3.
, hyphens-
or asterisks*
. - Links can be included with:
[my link to pubmed](http://pubmed.com)
- Images can be included with:
![alt text](https://bestmedicaljournal.com/study_graph.jpg "Image Title Text")
- For footnotes use
[^1](This is a footnote.)
inline. - Or use an inline reference
[^1]
to refer to a longer footnote elseweher in the document[^1]: This is a long footnote.
.